SHP2-IN-44

• Description :

  SHP2-IN-44 (Compound 26) is an allosteric and orally active SHP2 inhibitor with an IC50 of 27 nM. SHP2-IN-44 also inhibits ERK phosphorylation (IC50 of 299 nM) without off-target hERG activity. SHP2-IN-44 has a broad-spectrum anticancer activity, such as juvenile myelomonocytic leukemia, neuroblastoma and breast cancer. SHP2-IN-44 can be used for Noonan syndrome, LEOPARD syndrome and cancers research[1].

• UNSPSC :

  12352005

• Target :

  ERK; SHP2

• Related Pathways :

  MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Field of Research :

  Cancer

• Smiles :

  NC[C@@]1(C2=C(C=CC=C2)F)[C@]3([H])[C@@]1([H])CCN(C4=NC(N)=C(N=C4)SC5=CC=NC(N)=C5Cl)C3

• Molecular Formula :

  C22H23ClFN7S

• Molecular Weight :

  471.98

• References & Citations :

  [1]Sferrazza A, et al. Novel azabicyclic series of potent SHP2 allosteric inhibitors. Bioorg Med Chem Lett. 2025 Aug 19;129:130383.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2818955-47-2]